Synthetic peptide analog inhibitors of human immunodeficiency virus type 1 (HIV-1) protease were used to study the effects of inhibition of polyprotein processing on the assembly, structure, and infectivity of virions released from a T-celi line chronically infected with HIV-1. Inhibition of proteolytic processing of both Pr558w9 and Pr1609g W' was observed in purified virions from infected T cells after treatment. Protease inhibition was evident by the accumulation of precursors and processing intermediates of Pr655"' and by corresponding decreases in mature protein products. Electron microscopy revealed that the majority of the virion particles released from inhibitor-treated cells after a 24-h treatment had an immature or aberrant capsid morphology.
detectable infectivity. The fact that virions from treated cultures were unable to establish infection over the 7-to 10-day incubation period in the titration experiments strongly suggests that particles produced by inhibitor-treated cells were unable to reactivate to an infectious form when they were purified away from exogenous protease inhibitor. Thus, a block of HIV-1 protease processing of viral polyproteins by specific inhibitors results in a potent antiviral effect characterized by the production of noninfectious virions with altered protein structures and immature morphologies.
Retroviruses, including human immunodeficiency virus type 1 (HIV-1), contain a protease that is responsible for processing the initial translation products of theirgag andpol genes into functional proteins (8) . Pr55las and Pr1609'"" contain the nascent structural proteins and enzymes of the virion core in single polyprotein chains (5, 31, 35, 37, 38) . Proteolytic processing generates the gag and gag-pol protein products, each of which has a specific functional role in the fully formed virion (8, 20, 25) . Because of the essential roles of gag and gag-pol cleavage products in structure and enzymatic function, an active protease is required for the production of infectious virions. Indeed, mutations in the protease-coding region of HIV-1 proviruses result in the formation of noninfectious virions which exhibit immature capsid morphologies and reduced reverse transcriptase activities (14, 16, 29) . Although proviral mutants demonstrate the importance of the protease for the production of infectious virions, they do not necessarily predict the outcome of protease inhibitor-mediated inactivation of HIV-1 during ongoing chronic infection. It is possible that wild-type immature virions assembled in the presence of a competitive and reversible protease inhibitor might be able to "reactivate" to an infectious form when they are removed from contact with the drug (22) .
Rationally designed synthetic peptide analogs containing hydroxyethylene dipeptide isosteres are potent competitive * Corresponding author.
inhibitors of the protease (10) and inhibit processing of cell-associated gag and gag-pol polyproteins in chronically infected cells (23) . In addition, we and others have shown that protease inhibitors block acute infections of T-cell cultures (2, 11, 22, 23, 34) . However, none of those studies directly correlated a protease inhibitor block in polyprotein processing with an antiviral effect in the absence of free inhibitor. We used cells that were chronically infected with HIV-1 to investigate the effects of protease inhibitors on the virions that were produced because such cells have been implicated as a reservoir of infectious virus, perhaps contributing to the slow progressive nature of HIV-1-related disease (27, 30) . Understanding of the antiviral effects of protease inhibition on the biologic properties of virions will be important in addressing the application of these agents to the therapy of HIV-1 infections and AIDS.
An additional issue addressed in this study is whether virions assembled from chronically infected cell cultures in the presence of protease inhibitors are subsequently capable of infecting cells in the absence of inhibitor. We investigated the effects of cell-associated inhibition of polyprotein processing on the subsequent production, maturation, and infectivity of HIV-1 virions. Results of the studies described here provide important new information on the antiviral effects resulting from an exogenous blockade of viral polyprotein processing. MATERLALS AND METHODS Virus and cell lines. The H9, Molt-4, and AAS cells used in this study have been described previously (18, 26, 40) . All cell lines were maintained in RPMI 1640 medium containing 10% fetal bovine serum (FBS). H9/IIIB cells, which are chronically infected with the HTLV-IIIB virus isolate (31), were established in our laboratories as described previously (21, 23) and were used for the experiments described here.
Protease inhibitors. Compounds 1 to 5 (see Table 1 ) were prepared by solution-phase peptide condensation methods, as reported previously (10), by using the protected hydroxyethylene dipeptide isosteres Boc-NHCH(CH2Ph)CH[OSiMe2 (tert-Bu)]CHRCO2H, in which R is H or methyl (Me), Boc is tert-butoxycarbonyl, Ph is phenyl, and tert-Bu is tert-butyl. The synthesis of these hydroxyethylene isosteres will be described elsewhere (9) . Inhibitors were characterized by high-pressure liquid chromatography, proton nuclear magnetic resonance, and fast-atom-bombardment mass spectrometry. K1 values for compounds 1 to 3 obtained with recombinant HIV-1 protease were determined as described previously (10, 23) , while Ki values for the more potent compounds 4 and 5 were determined by a modification of the method described by Ackermann and Potter (1) as well as other investigators (6, 24) . For treatment of virus-infected cells, 10 mM solutions of inhibitors in 100% dimethyl sulfoxide (DMSO) were diluted into culture medium. Control cultures were treated with amounts of DMSO identical to those present in inhibitor-treated cultures. No toxicity, determined by trypan blue staining and viable cell counts, was observed with these inhibitors in the uninfected T-cell lines at concentrations of up to 100 ,uM compared with that in controls receiving identical amounts of DMSO.
Virion ultracentrifugation. About 6 ml of harvested cellfree culture supernatants was loaded onto a 5% sucrose cushion in phosphate-buffered saline (PBS) and centrifuged for 65 min at 30,000 rpm in an R40 rotor (Beckman). Virus pellets were resuspended in 1.2 ml of PBS, 0.2 ml of which was reserved for biochemical analyses and which represented a fivefold concentration of the starting material. The remaining sample (1 ml) was diluted to 5 ml with medium for virus infectivity assays. Ultracentrifugation did not damage virions, since the infectious titers of control virus following centrifugation were unchanged compared with those of an uncentrifuged aliquot kept on ice following centrifugation.
SDS-PAGE and Western blots (immunoblots). The proteins of virions recovered from the media containing treated cells were analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) (17) . Virion proteins were separated in 12.5% polyacrylamide gels at 40 mA per gel for 4 h and were electroblotted onto nitrocellulose filters (36) .
Western blot (immunoblot) detection of p24 and p17 gag proteins with monoclonal antibodies (Beckman) was carried out as described previously (23) . The HIV-1 envelope glycoprotein (gpl20) was detected with guinea pig antibodies to strain BH10 gpl20 V3 loop peptide (1:100) that were kindly provided by L. Ivanoff (SmithKline Beecham). Anti-guinea pig or anti-mouse immunoglobulin G antibodies conjugated with alkaline phosphatase (Bio-Rad, Richmond, Calif.) were used for the detection of protein-monoclonal antibody complexes.
Virus titration. The primary assessment of virion function was by titration of virus infectivity. Briefly, virion pellets were resuspended to their original volume in RPMI 1640 medium containing 10% FBS. Samples were serially diluted fivefold, and infectious titers were determined on either Molt-4 or AA5 cells in 24-well plates. For this, the medium of cultures was assayed for reverse transcriptase (RT) activity at 7 and 10 days postinfection as described previously (12, 39) , and the 50% tissue culture infectious dose (TCID50) endpoints were determined as described by Reed and Muench (32) .
Electron microscopy. H9/IIIB cells were treated for 24 h with 20 ,uM compounds 3, 4, and 5 (containing a final concentration of DMSO of 0.2%). Untreated controls received 0.2% DMSO in RPMI 1640 medium containing 10% FBS. Samples were prepared for electron microscopy as described previously (15) . Electron micrographs were printed at final magnifications of x40,000 to x50,000. Cellassociated virus particles from at least eight cells were evaluated, and the average percentage of virions with mature, immature, and indiscriminate capsid morphologies was calculated. Statistical analysis was performed with the SAS software package (SAS Institute Inc., Cary, N.C.).
RESULTS
Protease inhibitors. The structures of the inhibitors used in this study, along with their Ki values obtained with recombinant HIV-1 protease in vitro (7, 10) , the minimum concentrations required to show inhibition of gag processing in infected cells, and the concentrations that inhibit viral infectivity by 50% determined in an HIV-1 acute infectivity inhibition assay, are given in Table 1 pelleted through a 5% sucrose cushion. In virions from untreated controls, virions from DMSO carrier-treated controls, and virions from cultures treated with compound 2, little or no Pr55gag was detected; and most of the gag protein within these virions was processed into p24 and p17 subunits (Fig. 1A) . However, in virions purified from cultures treated with compounds 1 and 3, unprocessed Pr55ga& and two processing intermediates (p47 and p40) were detected. There was also a concomitant reduction of p24 and p17. With compound 3, nearly complete inhibition of processing of Pr559a& and the p47 and p40 intermediates to p24 and p17 (Fig. 1A, lane containing compound 3 ) was observed. According to earlier studies with cell-associated viral proteins (23) , the p47 band probably represents pl7-p24-p9 and the p40 band probably represents a mixture of pl7-p24 and p24-p9-p6 polyproteins (23, 25) .
On the basis of the relative amounts of virion gag proteins detected by Western blotting, protease inhibition did not appear to reduce the quantity of virus particles released from these cells. This point was difficult to quantitate more carefully by the p24 antigen capture assays, which only poorly detect p24 in the precursor forms, i.e., Pr55gag (19) . We therefore compared the relative levels of a second gene product, the envelope gpl20, since the processing of this molecule should be independent of viral protease inhibition. Relative levels of gpl20 in the pelleted virus from each of the treatment conditions were similar (Fig. 1B) .
In addition to compounds 1 to 3, inhibitors with significantly lower Ki values (Table 1) were also used to treat chronically infected cultures as described above. As seen in Fig. 1C , compounds 4 and 5 appeared to be more potent at inhibiting gag processing, with compound 5 being the most potent. Indeed, a new minor band that migrated just above p47 was resolved in virions from cells treated with these compounds and may indicate a unique cleavage event. The inhibition of gag-pol processing was also noted in the pelleted virions treated with compounds 3, 4, and 5 and probed with RT-directed monoclonal antibodies (data not shown). Results of these experiments demonstrated that treatment with protease inhibitors results in a blockade of processing ofgag and gag-pol proteins and an accumulation of unprocessed precursors in virion particles. Except for compound 2, the relative level of inhibition of gag processing correlated well with the relative potency (Ki) of the individual compounds in the recombinant protease assay ( Table 1) .
Effects of HIV-1 protease inhibition on virion morphology. The studies described above suggested that viruslike particles are assembled and released from inhibitor-treated cells into the medium. To test that possibility further, we examined these cells and supernatants after 24 h of treatment for retroviruslike particles by electron microscopy. HIV-1 virions with a mature morphology contain a cylindrical condensed nuclear core ( Fig. 2A) that is composed primarily of the p24 protein (13) . Detached, immature virions, i.e., those that do not contain condensed cores but that possess an electron-dense "annular" plaque similar in appearance to that seen at regions of budding virions associated with the viral membrane, are occasionally seen in control preparations (13) . Treatment of chronically infected cells for 24 h with any of the active protease inhibitors (Table 1) led to the appearance of mostly immature particles in the preparations examined (Fig. 2B) .
We investigated the relative numbers of mature and immature particles as a function of inhibitor treatment by quantitative analysis of virion morphology after a 24-h treatment with compounds 3, 4, and 5 ( Table 2) . While a 24-h treatment was not expected to totally eliminate the presence of mature virions, the inhibitors were found to significantly suppress the maturation profile, i.e., the number of mature/number of immature particles observed ultrastructurally. All samples contained a small percentage of particles that could not be clearly identified. Consistent with the gag processing inhibition results shown in Fig. 1C , compound 5 also yielded the highest fraction of immature particles in a 24-h treatment.
Infectivity of virus particles derived from inhibitor-treated cultures. Titration of the pelleted inhibitor-treated virions (Fig. 3 , day 1, lanes P) revealed that reduced levels of infectious virus were present at day 1 compared with the levels in DMSO-treated and untreated controls. In contrast VOL. 36, 1992 on January 18, 2018 by guest http://aac.asm.org/ Downloaded from to the results obtained on day 1, the infectivities of the virions separated from media on day 2 was detectable only in undiluted samples, and the infectivities of the virions in the day 3 sample was below the threshold of sensitivity of our assay. The pattern of infectivity inhibition closely correlates with the relative levels of immature and mature gag polypeptides, as indicated earlier in the Western blot analysis (Fig. 1) . Incubation of pelleted virions for up to 24 h at 370C in the absence of inhibitor did not result in the processing of a gag precursor (data not shown).
Titration of infectious virus in medium directly from the treated culture revealed no infectious virus (Fig. 3, lanes M) , suggesting that the inhibitor in the medium might have inhibited the subsequent infection of indicator T cells. Thus, determination of infectivity only from chronically infected cell supernatants containing protease inhibitor can be misleading because free inhibitor in the medium could block acute infection of T cells (23) . These results highlight the necessity of separating particles and virions from the inhibitor prior to assessing infectivity. Finally, results similar to those shown in Fig. 3 were obtained from experiments with compounds 3 and 4. The infectious titers of virus particles assembled after 3 days of continuous treatment were below the limit of detection (<20 TCID50s compared with 3,000 TCID50s in DMSO-treated controls). DISCUSSION Potent, small-molecule inhibitors of HIV-1 protease have been designed and have been shown to effectively prevent the acute infection of T cells in culture (10, 23) . In addition, these inhibitors prevented the cell-associated processing of Pr55gag and Pr1605a9P°precursor polyproteins in cultures of T cells chronically infected with HIV-1 (23) . The purpose of the present study was to correlate the consequence of HIV-1 protease inhibition with alterations in the infectivity, the morphology, and the gag polyprotein composition of virions produced by treated chronically infected cells.
The pattern of infectivity inhibition closely correlated with the relative levels of immature and mature virion gag polypeptides, as indicated by Western blot analysis (Fig. 1) . The fact that gpl20 levels were similar in different inhibitor treatments compared with the levels in untreated controls is consistent with the specific inhibition of the viral protease by active compounds and also indicates that the inhibitors did not have a major impact on the level of virus particle production over the time course of the experiment. Rather, the major effects are related to inhibition of processing of the gag-related precursors and to a reduction in the infectivities of the particles that were produced. This finding also extends to the virion-associated gag-pol precursors (data not shown), as we have reported earlier for cell-associated products (23) .
Mutations within the protease-coding region of HIV-1 proviruses result in noninfectious virions which exhibit an immature capsid morphology and reduced RT activity (14, 16, 29) . It is possible that wild-type immature virions assembled in the presence of a competitive reversible protease inhibitor might be able to reactivate to an infectious form when they are removed from drug. This has been demonstrated for gag processing within pseudovirions derived from vaccinia virus vectors with an inhibitor of moderate potency (22) .
Consistent with the results of Ashorn et al. (2) , no infectious virus was detectable in the supernatants of cells treated for only 1 day with a protease inhibitor (Fig. 3, day 1 , lane M). However, interpretation of this result could be complicated by the existence of free inhibitor in the medium, since HIV-1 protease inhibitors effectively block de novo infection of T-cell cultures by mature infectious virus particles (23) . In order to address this issue with virions from chronically infected cells, it was necessary to separate the virus from free inhibitor by gentle sedimentation prior to infectivity analysis. After 24 h of treatment, some mature particles were evident by electron microscopic analysis (Table 2) , and although the level was reduced compared with that of DMSO-treated control virions, some infectious virus was detectable at both days 1 and 2 (Fig. 3) . However, no infectious virus was detected in virions isolated after 3 days of treatment (Fig. 3) , suggesting that 1 to 2 days of treatment was necessary to completely remove the cell-associated mature virions that were present at the initial time of treatment. Significantly, the virus particles isolated at day 3 were unable to establish detectable infection in indicator T-cell lines after incubation periods of up to 10 days. This result strongly suggests that virus particles produced by inhibitor-treated chronically infected cells are unable to reactivate to an infectious form in the absence of exogenous protease inhibitor.
The results presented here extend the previous finding that protease inhibitors can inhibit the spread of virus in cultures acutely infected at low multiplicities (23) . The basis for this inhibitor-induced replication defect in acute infection is not completely understood but may be related to inhibition of early events in the HIV-1 replication cycle in addition to inhibition of maturation of budding particles. Recent studies suggesting that the NF-KB precursor may be processed by HIV-1 protease (4, 28, 33) as well as indications that a protease inhibitor blocked virus replication in early stages of HIV-1 infection (3) offer interesting possibilities for further investigations with this class of compounds. However, results of the studies described here demonstrate that HIV-1 protease inhibitors can also exert a potent antiviral effect on virions produced by chronically infected T-cell cultures, resulting in particles which are defective for infection. We interpret these results to indicate that treatment with an HIV-1 protease inhibitor has the potential to reduce or halt the production of infectious virus particles from both acutely and chronically infected cells. Whereas zidovudine and similar RT inhibitors have little or no effect on the production of infectious virions by chronically infected cells (30) , the effects of protease inhibitors on this type of infection suggests a clear operational distinction between their mechanism of action and that of nucleoside analog RT inhibitors. Thus, the unique mechanism of action of HIV-1 protease inhibitors supports the development of these compounds as an alternative or adjunct to current therapies such as zidovudine for the treatment of HIV-1 infection and AIDS.
